Watch Ticker

Allogene Therapeutics, Inc. Common Stock

Go to Allogene Therapeutics, Inc. Common Stock Website

$1.11

0.03 (2.78%)

Live

Previous Close

$1.08

Day Range

$1.1 - $1.19

Previous Day Range

$1 - $1.225

Market Cap

$236.2 million USD

Day Vol.

9.6 million

Previous Day Vol.

19.1 million

Currency

USD

Primary Exchange

Nasdaq

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-c...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Prnewswire - High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.

Related tickers: ONCY, CUE, VSTM, ALLO, CATX.

Read Full Article

N/A - Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Allogene Therapeutics presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma, showing promising results with a 31% confirmed response rate and durable responses in heavily pretreated patients.

Related tickers: ALLO.

Read Full Article

Trending Tickers

Please sign in to view